(KVT) Krynica Vitamin - Ratings and Ratios
Energy, Functional, Soft, Coffee, Dairy
Description: KVT Krynica Vitamin
Krynica Vitamin S.A. is a Polish beverage company with a diverse product portfolio that includes energy drinks, functional beverages, carbonated soft drinks, alcopops, coffee, and dairy drinks, catering to a broad customer base across Europe and beyond. The companys product offerings are packaged in various formats, including aluminum cans, PET bottles, and glass bottles, allowing it to adapt to different market preferences and distribution channels. In addition to its own branded products, Krynica Vitamin S.A. provides contract manufacturing services for other brands, leveraging its production capabilities to generate additional revenue streams.
With its headquarters in Warsaw, Poland, Krynica Vitamin S.A. operates as a subsidiary of Zinat Sp. Z O.O., indicating a level of corporate oversight and strategic guidance. The companys website (https://www.krynicavitamin.com) serves as a platform for communicating with stakeholders, showcasing its products, and potentially providing investor information.
Analyzing the companys stock performance, we observe that Krynica Vitamin S.A.s shares are currently trading at 9.68 PLN, slightly below its 20-day simple moving average (SMA20) of 10.02 PLN, indicating a potential short-term bearish trend. However, the stocks 50-day SMA stands at 9.39 PLN, suggesting a longer-term bullish outlook. The average true range (ATR) of 0.50 PLN, equivalent to 5.12% of the current price, implies moderate volatility. Considering the stocks 52-week high and low of 12.40 PLN and 8.00 PLN, respectively, we can infer that the current price is relatively closer to the lower end of its recent trading range.
From a fundamental perspective, Krynica Vitamin S.A.s market capitalization stands at 121.05M PLN, with a price-to-earnings (P/E) ratio of 9.88, indicating a relatively reasonable valuation. The companys return on equity (RoE) of 13.79% suggests a satisfactory level of profitability. By combining these fundamental insights with the technical analysis, we can forecast that Krynica Vitamin S.A.s stock may experience a moderate upward trend in the short to medium term, driven by its relatively attractive valuation and decent profitability. A potential price target could be around 11.00 PLN, representing a 13.6% increase from the current level, contingent upon the companys ability to maintain its profitability and navigate the competitive beverage market effectively.
KVT Stock Overview
Market Cap in USD | 34m |
Sub-Industry | Soft Drinks & Non-alcoholic Beverages |
IPO / Inception |
KVT Stock Ratings
Growth Rating | - |
Fundamental | 64.4% |
Dividend Rating | 1.03 |
Rel. Strength | -15.8 |
Analysts | - |
Fair Price Momentum | 8.79 PLN |
Fair Price DCF | 63.00 PLN |
KVT Dividends
Dividend Yield 12m | 2.79% |
Yield on Cost 5y | 5.01% |
Annual Growth 5y | -45.34% |
Payout Consistency | 44.2% |
Payout Ratio | 40.2% |
KVT Growth Ratios
Growth Correlation 3m | 71.5% |
Growth Correlation 12m | -19.3% |
Growth Correlation 5y | -79.1% |
CAGR 5y | 12.95% |
CAGR/Max DD 5y | 0.17 |
Sharpe Ratio 12m | -0.12 |
Alpha | -10.20 |
Beta | 0.364 |
Volatility | 40.25% |
Current Volume | 4.9k |
Average Volume 20d | 3.4k |
Stop Loss | 9.5 (-3.8%) |
Signal | 2.50 |
Piotroski VR‑10 (Strict, 0-10) 5.5
Net Income (14.3m TTM) > 0 and > 6% of Revenue (6% = 23.1m TTM) |
FCFTA 0.12 (>2.0%) and ΔFCFTA 7.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
NWC/Revenue -5.19% (prev -7.74%; Δ 2.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
CFO/TA 0.17 (>3.0%) and CFO 36.7m > Net Income 14.3m (YES >=105%, WARN >=100%) |
Net Debt (31.1m) to EBITDA (17.4m) ratio: 1.78 <= 3.0 (WARN <= 3.5) |
Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
Outstanding Shares last Quarter (12.3m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
Gross Margin 17.02% (prev 14.45%; Δ 2.57pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
Asset Turnover 172.3% (prev 166.1%; Δ 6.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
Interest Coverage Ratio 5.55 (EBITDA TTM 17.4m / Interest Expense TTM 3.14m) >= 6 (WARN >= 3) |
Altman Z'' 0.23
(A) -0.09 = (Total Current Assets 93.2m - Total Current Liabilities 113.2m) / Total Assets 220.8m |
(B) 0.06 = Retained Earnings (Balance) 13.2m / Total Assets 220.8m |
(C) 0.08 = EBIT TTM 17.4m / Avg Total Assets 223.6m |
(D) 0.10 = Book Value of Equity 13.2m / Total Liabilities 125.8m |
Total Rating: 0.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.37
1. Piotroski 5.50pt = 0.50 |
2. FCF Yield 16.63% = 5.0 |
3. FCF Margin 6.63% = 1.66 |
4. Debt/Equity 0.33 = 2.45 |
5. Debt/Ebitda 1.79 = 0.42 |
6. ROIC - WACC 5.86% = 7.33 |
7. RoE 15.49% = 1.29 |
8. Rev. Trend -10.09% = -0.50 |
9. Rev. CAGR -7.63% = -1.27 |
10. EPS Trend data missing |
11. EPS CAGR -34.29% = -2.50 |
What is the price of KVT shares?
Over the past week, the price has changed by +0.82%, over one month by +2.49%, over three months by +3.70% and over the past year by -0.57%.
Is Krynica Vitamin a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KVT is around 8.79 PLN . This means that KVT is currently overvalued and has a potential downside of -11.03%.
Is KVT a buy, sell or hold?
What are the forecasts/targets for the KVT price?
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 9.6 | -2.8% |
KVT Fundamental Data Overview
Market Cap PLN = 122.5m (122.5m PLN * 1.0 PLN.PLN)
CCE Cash And Equivalents = 48.0k PLN (Cash only, last quarter)
P/E Trailing = 8.547
P/S = 0.3178
P/B = 1.2903
Beta = -0.541
Revenue TTM = 385.3m PLN
EBIT TTM = 17.4m PLN
EBITDA TTM = 17.4m PLN
Long Term Debt = 8.92m PLN (from longTermDebt, last quarter)
Short Term Debt = 22.2m PLN (from shortLongTermDebt, last quarter)
Debt = 31.1m PLN (Calculated: Short Term 22.2m + Long Term 8.92m)
Net Debt = 31.1m PLN (from netDebt column, last quarter)
Enterprise Value = 153.6m PLN (122.5m + Debt 31.1m - CCE 48.0k)
Interest Coverage Ratio = 5.55 (Ebit TTM 17.4m / Interest Expense TTM 3.14m)
FCF Yield = 16.63% (FCF TTM 25.5m / Enterprise Value 153.6m)
FCF Margin = 6.63% (FCF TTM 25.5m / Revenue TTM 385.3m)
Net Margin = 3.71% (Net Income TTM 14.3m / Revenue TTM 385.3m)
Gross Margin = 17.02% ((Revenue TTM 385.3m - Cost of Revenue TTM 319.7m) / Revenue TTM)
Tobins Q-Ratio = 11.68 (Enterprise Value 153.6m / Book Value Of Equity 13.2m)
Interest Expense / Debt = 1.82% (Interest Expense 568.0k / Debt 31.1m)
Taxrate = 11.44% (from yearly Tax Provision: 1.58m / 13.8m)
NOPAT = 15.4m (EBIT 17.4m * (1 - 11.44%))
Current Ratio = 0.82 (Total Current Assets 93.2m / Total Current Liabilities 113.2m)
Debt / Equity = 0.33 (Debt 31.1m / last Quarter total Stockholder Equity 95.0m)
Debt / EBITDA = 1.79 (Net Debt 31.1m / EBITDA 17.4m)
Debt / FCF = 1.22 (Debt 31.1m / FCF TTM 25.5m)
Total Stockholder Equity = 92.3m (last 4 quarters mean)
RoA = 6.47% (Net Income 14.3m, Total Assets 220.8m )
RoE = 15.49% (Net Income TTM 14.3m / Total Stockholder Equity 92.3m)
RoCE = 17.23% (Ebit 17.4m / (Equity 92.3m + L.T.Debt 8.92m))
RoIC = 12.06% (NOPAT 15.4m / Invested Capital 128.0m)
WACC = 6.20% (E(122.5m)/V(153.7m) * Re(7.36%)) + (D(31.1m)/V(153.7m) * Rd(1.82%) * (1-Tc(0.11)))
Shares Correlation 5-Years: -86.60 | Cagr: -0.00%
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.90% ; FCFE base≈19.2m ; Y1≈24.6m ; Y5≈45.6m
Fair Price DCF = 63.00 (DCF Value 771.9m / Shares Outstanding 12.3m; 5y FCF grow 30.0% → 3.0% )
Revenue Correlation: -10.09 | Revenue CAGR: -7.63%
Revenue Growth Correlation: 0.45%
EPS Correlation: N/A | EPS CAGR: -34.29%
EPS Growth Correlation: 6.19%